Glenmark’s Q4FY26 profit surged to ₹301.4 crore, marking a rise of over 6,400% from ₹4.6 crore a year earlier. Shares of Glenmark Pharmaceuticals Ltd ended at ₹2,274.25, down by ₹108.40, or 4.55%, on the BSE today, May 30.
1 Min Read
Revenue for the quarter rose 15.8% year-on-year to ₹3,770.5 crore, up from ₹3,256.2 crore. On a gross unit basis, EBITDA increased 35.9% to ₹762.5 crore from ₹561.1 crore. EBITDA margin expanded to 20.2% from 17.2% in the corresponding quarter of the previous year.
ALSO READ | Glenmark’s US arm settles generic drug pricing case for $29.6 million
The company also recommended a dividend of 250%, translating to ₹2.5 per equity share of face value ₹1 each, for FY26. The dividend is subject to approval by shareholders at the upcoming annual general meeting.
Shares of Glenmark Pharmaceuticals Ltd ended at ₹2,274.25, down by ₹108.40, or 4.55%, on the BSE today, May 29.
(Edited by : Shoma Bhattacharjee)
First Published: May 29, 2026 8:51 PM IST
